TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8179658

Group type: EXPERIMENTAL
Intervention: Nicotine 2 mg chewing gum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine 4 mg chewing gum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (gum and patch)
Number of subjects: 40
Study: 2636484

Group type: EXPERIMENTAL
Intervention: Ultraviolet light treatment of 50 ml venous blood
Number of subjects: 28

Group type: COMPARATOR
Intervention: Feigned exposure to ultraviolet rays (Control)
Number of subjects: 28
Study: 8436158

Group type: EXPERIMENTAL
Intervention: Allomaron (allopurinol 100 mg plus benzbromarone 20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Zyloprim (allopurinol 100 mg)
Number of subjects: 14
Study: 749193

Group type: EXPERIMENTAL
Intervention: Concurrent hormonal therapy with combination chemotherapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Hormonal therapy alone (control)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Chemotherapy programs (further random allocation)
Number of subjects: 210
Study: 31774494

Group type: EXPERIMENTAL
Intervention: Training models for implementing evidence-based psychological treatment
Number of subjects: 0
Study: 30418475

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 6991

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 6991
Study: 28322125

Group type: EXPERIMENTAL
Intervention: Anatomy-specific virtual reality (VR) surgical rehearsal
Number of subjects: 16
Study: 26721747

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low-impact exercise
Number of subjects: 96
Study: 24395863

Group type: COMPARATOR
Intervention: Cisplatin (CIS) chemoradiotherapy
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Cisplatin (CIS) and tirapazamine (TPZ) chemoradiotherapy
Number of subjects: 402
Study: 22623466

Group type: EXPERIMENTAL
Intervention: Brushing with a whitening dentifrice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brushing with a conventional dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Brushing without a dentifrice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brushing with both conventional and whitening dentifrices
Number of subjects: 10

Group type: COMPARATOR
Intervention: All experimental conditions
Number of subjects: 10
Study: 19632949

Group type: EXPERIMENTAL
Intervention: S-1 (oral fluoropyrimidine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-1 combined with platinum compounds, irinotecan, and gemcitabine
Number of subjects: 0
Study: 18158074

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 322
Study: 15349107

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octylcyanoacrylate)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard suture
Number of subjects: 133
Study: 11906552

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant concurrent chemoradiotherapy (PCCRT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Postoperative adjuvant radiotherapy (PRT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (PCT)
Number of subjects: 80
Study: 9832218

Group type: EXPERIMENTAL
Intervention: Frolova primary palatoplasty technique
Number of subjects: 112

Group type: COMPARATOR
Intervention: Furlow double-Z palatoplasty
Number of subjects: 112
Study: 8031705

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg, once daily)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Enalapril (10-40 mg, once daily)
Number of subjects: 461
Study: 2590930

Group type: EXPERIMENTAL
Intervention: 7F catheter (hand injection)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 5F catheter (hand injection)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 5F catheter (power injection)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 5F catheter (second catheter used)
Number of subjects: 29
Study: 5090759

Group type: EXPERIMENTAL
Intervention: Dermatological treatment plus psychiatric treatment (limited to four months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dermatological treatment only
Number of subjects: 72
Study: 28974124

Group type: EXPERIMENTAL
Intervention: Low-dose Dhaka regime
Number of subjects: 402

Group type: COMPARATOR
Intervention: Loading dose only regime
Number of subjects: 402
Study: 25894749

Group type: EXPERIMENTAL
Intervention: Early post-operative rehabilitation (EPR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Post-operative cast immobilization (PCI)
Number of subjects: 57
Study: 25459393

Group type: EXPERIMENTAL
Intervention: Paclitaxel and bevacizumab with capecitabine (ATX)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Paclitaxel and bevacizumab without capecitabine (AT)
Number of subjects: 268
Study: 22381714

Group type: EXPERIMENTAL
Intervention: Avagacestat (0.3 to 800 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20299490

Group type: EXPERIMENTAL
Intervention: Testosterone and dutasteride
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Testosterone and anastrozole
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Triple stimulus (GHRP-2/GHRH/l-arginine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Somatostatin (SS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5alpha-dihydrotestosterone (DHT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Abdominal visceral fat (AVF)
Number of subjects: 42
Study: 18821268

Group type: EXPERIMENTAL
Intervention: Retrieval opportunities (3 within-list retrieval opportunities for half the names) during multitasking in Experiment 1
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Retrieval opportunities (3 additional appearances in the video without repeating names) for 8 of the 12 residents in Experiment 2
Number of subjects: 293
Study: 16334715

Group type: EXPERIMENTAL
Intervention: Acupuncture at points of the Du Channel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (10-day decrescendo therapy of methadone only)
Number of subjects: 70
Study: 12921571

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (Group A) - chemotherapy with 5‐fluorouracil and cisplatin for 2 cycles and radiotherapy of DT36 Gy/12 f/17 d followed by surgery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (Group B) - operation alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (Group A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 97
Study: 11234740

Group type: EXPERIMENTAL
Intervention: Tetanus and diphtheria toxoids adsorbed (Td)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aluminum hydroxide adjuvant (alum)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: VAQTA (hepatitis A vaccine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HAVRIX (hepatitis A vaccine)
Number of subjects: 200
Study: 9438143

Group type: EXPERIMENTAL
Intervention: Formoterol (2 x 24 micrograms)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Salbutamol (4 x 200 micrograms)
Number of subjects: 22
Study: 1623705

Group type: EXPERIMENTAL
Intervention: Conventional restorative treatment
Number of subjects: 52
Study: 6442168

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 15
Study: 31277674

Group type: EXPERIMENTAL
Intervention: Symptom burden
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Activities of daily living
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Change in symptom burden over a two-year period
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Depression at baseline
Number of subjects: 238
Study: 30785252

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 251

Group type: COMPARATOR
Intervention: Mitral valve repair
Number of subjects: 251
Study: 27687344

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 90
Study: 24867312

Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preserved latanoprost (group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Preserved timolol (group 4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vehicle of latanoprost or physiological buffered saline solution (group 5 and 6)
Number of subjects: 80
Study: 23236031

Group type: EXPERIMENTAL
Intervention: Education in skin care and individual counselling
Number of subjects: 255

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 255
Study: 20625052

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 53 letters (6/6(-2))
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 45 letters (6/9.5) for myopia
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 57 letters (6/6(+2)) for hyperopia
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 55 letters (6/6) for astigmatism
Number of subjects: 4497
Study: 19016201

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime 1 mg in 0.1 mL isotonic NaCl solution
Number of subjects: 16211

Group type: COMPARATOR
Intervention: Topical levofloxacin 0.5%
Number of subjects: 16211

Group type: COMPARATOR
Intervention: Clear corneal incision (CCI)
Number of subjects: 16211

Group type: COMPARATOR
Intervention: Silicon based IOL optic material
Number of subjects: 16211

Group type: COMPARATOR
Intervention: Intraoperative complications
Number of subjects: 16211
Study: 16261220

Group type: EXPERIMENTAL
Intervention: Bicyclol 150 mg daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bicyclol 75 mg daily
Number of subjects: 31
Study: 12021520

Group type: EXPERIMENTAL
Intervention: Me‐Cbl 500 microg twice/week plus FA 10 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: FA 10 mg/day alone
Number of subjects: 62

Group type: COMPARATOR
Intervention: No vitamin supplementation (Control Group C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Me‐Cbl 500 microg twice/week alone (Control Group D)
Number of subjects: 62
Study: 10526812

Group type: EXPERIMENTAL
Intervention: Abdominal wall lift
Number of subjects: 12

Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum
Number of subjects: 12
Study: 8748363

Group type: EXPERIMENTAL
Intervention: Low-fat nutrition support (15% of total calories as fat)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low-fat nutrition support with fish oil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (35% fat)
Number of subjects: 43
Study: 1835324

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (54 micrograms after the first isoetharine treatment and 36 micrograms after the second and fourth treatments)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard regimen of nebulized isoetharine (0.5 mL of a 1% solution diluted to 2.0 mL with normal saline every hour)
Number of subjects: 55
Study: 7258283

Group type: EXPERIMENTAL
Intervention: +1.25 D added to distance correction with 2 delta base-in each eye (plus-with-prism group)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Bifocals incorporating distance correction with a +1.50 D near addition (bifocal group)
Number of subjects: 232

Group type: COMPARATOR
Intervention: No. 1 pink tint glasses for reading (placebo group)
Number of subjects: 232
Study: 31113987

Group type: EXPERIMENTAL
Intervention: esaxerenone 1.25 mg/day
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: esaxerenone 2.5 mg/day
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: esaxerenone 5 mg/day
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: eplerenone (50–100 mg/day)
Number of subjects: 426

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study: 26445894

Group type: EXPERIMENTAL
Intervention: Teleconferencing system facilitated by trained volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26514931

Group type: EXPERIMENTAL
Intervention: Amoxicillin 100mg/kg/day + 0.9% NSI
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo + 0.9% NSI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amoxicillin + 0.9% NSI
Number of subjects: 62
Study: 25073939

Group type: EXPERIMENTAL
Intervention: High intensity ambulatory rehabilitation programmes (≥ 3 × 1‐h weekly sessions for approximately 10 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care programmes (≤ 2 × 1‐h weekly sessions)
Number of subjects: 59
Study: 21084399

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (25-75 mg daily)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 19953325

Group type: EXPERIMENTAL
Intervention: Social Development Classroom Curriculum (SDC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School/Family/Community (SC) intervention curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Enhancement Curriculum (HEC) attention placebo control
Number of subjects: 0
Study: 17556785

Group type: EXPERIMENTAL
Intervention: Combination training (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study: 15191514

Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin and tinidazole twice‐daily
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin and tinidazole once‐daily
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo, clarithromycin and tinidazole once‐daily
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin and tinidazole (both dosing regimens)
Number of subjects: 205
Study: 11753827

Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis against cytomegalovirus (CMV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 36
Study: 9834046

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg 4 times a day) for 10 days with concomitant clarithromycin (500 mg twice a day) from days 6 through 10
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice a day) for 10 days combined with cisapride (10 mg 4 times a day) from days 6 through 10
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cisapride (10 mg 4 times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice a day)
Number of subjects: 12
Study: 9706623

Group type: EXPERIMENTAL
Intervention: Vigabatrin 150 mg/kg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vigabatrin 65-75 mg/kg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vigabatrin (both dosages)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vigabatrin (responders)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ACTH (in non-responders)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Valproic acid (in non-responders)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonazepam (in non-responders)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EEG (last visit)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 28
Study: 1885830

Group type: EXPERIMENTAL
Intervention: Polytrimethylene carbonate (Maxon)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Polyglactic acid (Vicryl)
Number of subjects: 584
Study: 6859570

Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural morphine 7.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular morphine 7.5 mg
Number of subjects: 40
Study: 31595302

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30571289

Group type: EXPERIMENTAL
Intervention: HIT-treadmill
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HIT-stepper
Number of subjects: 16

Group type: COMPARATOR
Intervention: MCT-treadmill
Number of subjects: 16
Study: 28214664

Group type: EXPERIMENTAL
Intervention: Music listening during blood draw skill practice
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 73
Study: 26805940

Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with suspension of the uterosacral ligaments
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 208
Study: 24456991

Group type: EXPERIMENTAL
Intervention: Vitamin-D supplementation
Number of subjects: 104
Study: 22537824

Group type: EXPERIMENTAL
Intervention: Smoking (ever vs. never)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: HLA-DRB1 shared-epitope (SE) alleles
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: SE-positive smokers
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Interaction between smoking and SE alleles
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*04:05 SE allele
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Smoking and SE alleles combination
Number of subjects: 1676
Study: 20167988

Group type: EXPERIMENTAL
Intervention: Pre-emptive therapy with valganciclovir (n=36)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Valacyclovir prophylaxis (n=34)
Number of subjects: 70
Study: 17414805

Group type: EXPERIMENTAL
Intervention: Postexercise hypotension (PEH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) induced hypotension
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold pressor (CP) during PEH
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resting baseline
Number of subjects: 10
Study: 15858814

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus stimulation (n=11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Optimized pharmacological treatment (n=8)
Number of subjects: 19
Study: 11932658

Group type: EXPERIMENTAL
Intervention: MIVS technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 20
Study: 9147710

Group type: EXPERIMENTAL
Intervention: Egifilin 200 mg retard tablet
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Egifilin 400 mg retard tablet
Number of subjects: 26
Study: 8372753

Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (for women 40-49 years old)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (for women 50-59 years old)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care after an initial physical examination (for women 40-49 years old)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual physical examination only (for women 50-59 years old)
Number of subjects: 0
Study: 3555852

Group type: EXPERIMENTAL
Intervention: Physostigmine and lecithin combination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lecithin alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29883807

Group type: EXPERIMENTAL
Intervention: Whole body vibration with unstable shoes
Number of subjects: 59

Group type: COMPARATOR
Intervention: Whole body vibration with standard shoes
Number of subjects: 59
Study: 25845833

Group type: EXPERIMENTAL
Intervention: Wish group (positive intervention)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 124
Study: 24439980

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 928

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 928
Study: 22884040

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Infliximab treatment group
Number of subjects: 129
Study: 20972285

Group type: EXPERIMENTAL
Intervention: RUTF (locally produced energy-dense supplement)
Number of subjects: 96

Group type: COMPARATOR
Intervention: HCCM (High Calorie Cereal Milk)
Number of subjects: 96
Study: 18333868

Group type: EXPERIMENTAL
Intervention: Maraviroc 900 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (active comparator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc (up to 2363 ng ml(‐1))
Number of subjects: 0
Study: 16122484

Group type: EXPERIMENTAL
Intervention: Alternate suction (suction overnight and water seal during the day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Water seal alone
Number of subjects: 94
Study: 12741449

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients with duodenal ulcer (DU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients with gastric ulcer (GU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients with ulcer-free gastritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori eradication in DU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori eradication in GU
Number of subjects: 0

Group type: COMPARATOR
Intervention: H. pylori-negative controls
Number of subjects: 0
Study: 10574587

Group type: EXPERIMENTAL
Intervention: Postoperative AAA patients (postop-AAA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Preoperative AAA patients (preop-AAA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Age-matched healthy controls (AMC)
Number of subjects: 18
Study: 8554016

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (intravenous thrombolytic agents or urgent percutaneous transluminal coronary angioplasty)
Number of subjects: 20